Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Ce…
Based on feedback from the FDA, Stemline remains on track to begin submission of its BLA in the 4Q17-1Q18 timeframe.
Source: BioSpace
Based on feedback from the FDA, Stemline remains on track to begin submission of its BLA in the 4Q17-1Q18 timeframe.
Source: BioSpace